The importance of pretreatment testosterone and other prognostic variables in the response to androgen deprivation therapy.
Department of Urology, University of Tennessee, Memphis.
M S
MS
Soloway
D000726:Androgen Antagonists / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D003131:Combined Modality Therapy; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D009376:Neoplasms, Hormone-Dependent / Q000097:blood / Q000188:drug therapy*; D009919:Orchiectomy; D011379:Prognosis; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011877:Radionuclide Imaging; D013739:Testosterone / Q000097:blood*
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone